Kenvue stock has delivered a 9.3% gain year to date. Its current share price of US$18.93 still sits well below an intrinsic value estimate from a Discounted Cash Flow (DCF) model, which points to a 36.4% discount. At the same time, traditional earnings multiples suggest the shares look about fairly priced, leaving investors weighing a clear DCF upside signal against more neutral market ratios. Year to date, Kenvue is up 9.3%, indicating the market has already repriced the stock higher even...

In August 2026, Kenvue’s Zyrtec brand launched Zyrtec Allergen Shield Spray, a drug-free nasal mist that forms a gel barrier in the nose within minutes to help block common airborne allergens like pollen, pet dander, and dust for up to six hours in adults and children aged 12 and older. This first-of-its-kind, HPMC-based spray expands Zyrtec’s toolkit toward proactive allergen defense, signaling Kenvue’s push into drug-free, preventative allergy solutions. We’ll now examine how this new...

Johnson & Johnson's new drugs may offset declining sales due to patent-protection losses.

Panettiere's death has re-ignited calls to boycott Neutrogena, which she said ended a partnership after she spoke out about postpartum depression.

Zyrtec Allergen Shield Spray, a new drug free nasal mist from Kenvue (KVUE), has given investors fresh product news to weigh. The launch highlights activity in the company’s Self Care allergy portfolio. See our latest analysis for Kenvue. The recent Zyrtec Allergen Shield Spray launch comes after Kenvue reported second quarter 2026 sales of US$3,955 million and net income of US$456 million on August 6, while also completing a US$439.14 million share repurchase program that covered 20,387,000...

Personal care products provider Kimberly-Clark Corporation (NYSE:KMB)’s shares are down by 17% over the past year and are up by 9% year-to-date. It is currently undergoing a major transformation through acquiring Kenvue. Cramer has discussed Kimberly-Clark Corporation (NYSE:KMB)’s acquisition several times and linked its performance with consumer goods giant Procter & Gamble. In his morning […]

KVUE's Q2 sales and earnings miss estimates, but organic growth improved as Skin Health and Beauty led a broader recovery.

Kenvue just snapped a four-quarter earnings streak while Reddit falls nearly silent, and the reason why tells you everything about where this stock goes next.

Sales and earnings increased across Kenvue's portfolio, but tariffs, inflation and currency costs reduced profitability.

Kenvue posts higher Q2 sales and earnings, but both miss estimates as inflation, tariffs and foreign exchange pressure margins.

Kenvue Inc (NYSE:KVUE) shares fell about 2% on Thursday after the consumer health company reported second quarter results that narrowly missed Wall Street expectations, while margins declined from a year earlier. The company reported adjusted diluted earnings per share of $0.31, compared with...

Kenvue (KVUE) delivered earnings and revenue surprises of -3.13% and -0.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

US equity markets were mostly pointing higher before the opening bell Thursday as investors assess p

Kenvue reported higher profit and sales in the second quarter, boosted by higher prices and volumes, as the company continues working to turn around its business ahead of its acquisition by Kimberly-Clark.

Today Economic data: Weekly jobless claims, preliminary productivity and costs report for the second quarter, EIA weekly natural gas storage report, Challenger job-cuts report Earnings (a.m.): ConocoPhillips, Warner Bros Discovery, Kenvue, Fox Corp, Hertz, Keurig Dr Pepper, Datadog, Ralph Lauren Earnings (p.

Kimberly-Clark's (KMB) Q2 earnings beat showed the company can deliver steady profit growth despite

Today Federal Reserve speakers: Fed governor Lisa Cook Economic data: the Energy Information Administration’s weekly petroleum status report, U.S. services PMI, global services PMI, ADP employment survey Earnings (a.

Kimberly-Clark stock has fallen 15.9% over the past year, yet an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach currently points to the shares trading at a sizeable discount to that estimate, while broader checks and earnings multiples suggest something closer to a fair price. The 15.9% share price decline over the last 12 months reflects weaker recent returns, which can matter if the market is reassessing Kimberly-Clark’s prospects. The planned acquisition of...

Today Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...

KVUE is expected to post Q2 revenue and earnings growth as brand strength, innovation and productivity efforts offset seasonal and cost pressures.

Church & Dwight (CHD) delivered earnings and revenue surprises of 0.00% and +1.79%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

KVUE's trusted brands, margin gains and pending Kimberly-Clark deal shape its outlook amid mixed growth signals.

KVUE's margin gains and stronger cash flow boost its appeal, but slow organic growth, debt and deal uncertainty keep the outlook balanced.

Kenvue's beauty momentum, margin expansion and stronger cash flow support its outlook as uneven demand and deal uncertainty temper visibility.

Kenvue has lagged the broader market over the past year, leaving analysts with a measured view on the stock.

Black Monday wiped out 22% of the market in a single day, and most investors never saw it coming. A small group of companies not only survived that crash and every major meltdown since, but kept sending bigger checks to shareholders each time the panic peaked.

Kenvue recently received FDA approval for Tylenol with Naproxen, a new over-the-counter pain reliever offering up to 12 hours of pain relief and slated for distribution across major U.S. retailers. This product launch adds a differentiated option to Kenvue’s Self Care portfolio, potentially strengthening the Tylenol brand’s position in the competitive pain relief category. Next, we’ll examine how the FDA approval of Tylenol with Naproxen could influence Kenvue’s investment narrative and...

Kenvue stock has delivered a decline of 11.7% over the past year, yet the current Discounted Cash Flow (DCF) intrinsic value estimate indicates the shares may trade at a sizeable discount to that model, while market based multiples look closer to fair. Over the past 12 months, Kenvue is down 11.7%, which puts recent gains into context as a recovery rather than a clear winning streak. Investor expectations for the consumer health portfolio and cash flow resilience can support the DCF view of...

The FDA’s approval of Tylenol with Naproxen, a new over the counter pain reliever offering up to 12 hours of relief, has put Kenvue (KVUE) in focus after the stock gained about 2%. See our latest analysis for Kenvue. The FDA decision appears to have added to existing momentum in Kenvue’s stock, with a 90 day share price return of 10.23% and an 11.32% year to date share price return, even though the 1 year total shareholder return is down 11.67%. If this kind of news driven move has you...

The newly approved product is the first and only fixed-dose combination of acetaminophen and naproxen sodium available without a prescription.

On Tuesday’s episode of CNBC’s Mad Money, Jim Cramer highlighted Kimberly-Clark Corporation (NYSE:KMB) as a defensive holding for investors looking to lock in profits from high-flying technology stocks and reallocate into lower-risk value plays. After years of sluggish price action, Cramer noted that the consumer giant has finally established a stable bottom, anchored by a […]

Kenvue heads into its second-quarter earnings release with analysts projecting low double-digit EPS growth.

The report said Principal Financial had expressed interest earlier this year, but nothing came of the approach.

While growth investors scrambled for cover in 2026, a quiet group of battle-tested income stocks started leaving the S&P 500 in the dust. Four Dividend Kings with decades of unbroken payouts are now posting returns that would make most momentum traders jealous, and Wall Street thinks they still have room to run.

Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 0.2% and